Marker Therapeutics Inc reports results for the quarter ended in January - Earnings Summary

Marker Therapeutics

15/08/2024 08:39

* Marker Therapeutics Inc  MRKR.OQ  reported a quarterly
adjusted
loss of 29 cents​​ per share for the quarter ended in January. 
The lone analyst forecast for the quarter was for a loss of 43
cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Marker Therapeutics Inc's reported EPS for the quarter was
a
loss of 29 cents​.
    * The company reported a quarterly loss of $2.19 million.
    * Marker Therapeutics Inc shares had fallen by 38.1% this
quarter and lost 38.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 60.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Marker
Therapeutics Inc is $11.75 
This summary was machine generated from LSEG data August 15 at
07:38 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.43          -0.29          Beat
 Mar. 31 2024      -0.25          -0.27          Missed